NeuroKaire – a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology – announced it had secured $10 million in funding to advance the development of its clinical test, which helps identify drug efficacy for depression patients. GreyBird Ventures led the round. The company’s other investors include Meron Capital Jumpspeed Ventures, among others.
The funding will help the company scale operations and further expand pharmaceutical partnerships.
Based on a simple blood draw, NeuroKaire can provide a new view into brain function, including drug response insights based on individual patients’ combined neurobiology and clinical context.
This test can help clinicians identify the optimal antidepressant based on the unique response of the patient’s brain cells. And this test includes the first-ever readout of antidepressant effects from each patient’s derived neurons, clinical data, and a pharmacogenetic screening covering 132 drugs.
KEY QUOTES:
“NeuroKaire has the potential to improve outcomes for depression patients. The company’s neuronal readout may represent the next generation of screening to help clinicians efficiently identify potential drug efficacy for their patients.”
- Maurizio Fava, MD, Head of the Department of Psychiatry at Brigham and Womens Hospital Harvard Medical School, Psychiatrist in Chief Psychiatry, Massachusetts General Hospital, and an internationally recognized clinician, researcher, and teacher in psychiatry
“This funding will help us scale operations, expand our team, and deepen research and development efforts. Our test represents a major leap forward in the available tools that enable doctors to practice precision medicine in mental health. The investment will also support NeuroKaire in expanding its network of pharmaceutical partnerships currently focused on multiple psychiatric and neurological diseases. These collaborations are driving continued innovation in drug discovery and development and help ensure that new medications reach the right patients as quickly as possible.”
- Founder and CEO Talia Cohen Solal
“We are proud to support NeuroKaire in their mission to advance precision medicine in psychiatry and neurology through groundbreaking technologies. NeuroKaire has the potential to transform treatment paradigms in depression. We are excited to help bring the company’s innovative test to the clinic for treatment optimization and to see it used to improve the efficiency of new drug development.”
- Scott Gazelle, Managing Partner of GreyBird Ventures
